¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"active site-directed irreversible inhibitor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • active shielding
    ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
  • active site
    Ȱ¼ººÎÀ§
  • active transport
    ´Éµ¿¿î¹Ý
  • active treatment
    Àû±ØÄ¡·á
  • active tuberculosis
    Ȱµ¿°áÇÙ
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • chronic active photosensitive dermatitis
    ¸¸¼ºÈ°¼º±¤¼±°ú¹ÎÇǺο°
  • MR active nuclei
    ÀÚ±â°ø¸íȰ¼ºÇÙ
  • surface-active disinfectant
    Ç¥¸éȰ¼º¼Òµ¶Á¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • active site
    Ȱ¼ººÎÀ§
  • active transport
    ´Éµ¿¿î¹Ý
  • active treatment
    Àû±ØÄ¡·á
  • active tuberculosis
    Ȱµ¿°áÇÙ
  • active gradient shielding
    ´Éµ¿±â¿ï±âÂ÷Æó, ´Éµ¿°æ»çÂ÷Æó
  • active incorporative mode
    Àû±ØÇÔÀÔ¾ç½Ä
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª
  • chronic active photosensitive dermatitis
    ¸¸¼ºÈ°¼º±¤¼±°ú¹ÎÇǺο°
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • surface-active disinfectant
    Ç¥¸éȰ¼º¼Òµ¶Á¦, °è¸éȰ¼º¼Òµ¶Á¦
  • metabolically active stone
    ´ë»çȰ¼ºµ¹
  • MR active nuclei
    ÀÚ±â°ø¸íȰ¼ºÇÙ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • active oxygen
    Ȱ¼º»ê¼Ò(üÀàõß«áÈ).
  • active shielding
    ´Éµ¿ Â÷Æó
  • active shimming
    ´Éµ¿ º¸Á¤
  • active site
    Ȱ¼ºÀÚ¸®.
  • active spot
    Ȱ¼ºÁ¡(üÀàõïÇ).
  • active tension
    ´Éµ¿Àå·Â(ÒöÔÑíåæ³)
  • active transport
    ´Éµ¿(Àû)¿î¹Ý(¡­îÜê¡Úæ), ´Éµ¿(Àû)¼ö¼Û(ÒöÔÑîÜâÃáê)
  • active treatment
    Á÷Á¢Ä¡·á, Àû±Ø¿ä¹ý(îÝпèþÛö).
  • active tuberculosis
    Ȱµ¿¼º °áÇÙ(Áõ)(üÀÔÑàõÌ¿ú·ñø).
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª.
  • hepatitis,chronic active
    ¸¸¼ºÈ°µ¿¼º(Ø·àõüÀÔÑàõ)
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • positive placebo =active p.
    ¾ç¼ºÇö󼼺¸, Ç¥Áؾà(øöñÞå·).
  • probe electrode =active e.
    Ž»öÀü±Ø.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • disinfectant, surface-active
    °è¸éȰ¼º¼Òµ¶Á¦
  • hepatitis,chronic active
    ¸¸¼ºÈ°µ¿¼º(Ø·àõüÀÔÑàõ)
  • immunity, active
    ´Éµ¿¸é¿ª
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • metabolically active stone
    ´ë»ç(¼º)Ȱ¼º(È­)°á¼®
  • positive placebo =active p.
    ¾ç¼ºÇö󼼺¸, Ç¥Áؾà(øöñÞå·).
  • probe electrode =active e.
    Ž»öÀü±Ø.
  • surface active disinfectant
    Ç¥¸éȰ¼º»ì±Õ¾à.
  • acetylcholinesterase inhibitor
    ¾Æ¼¼Æ®Äݸ°¿¡½ºÅÍ·¹À̽º<¿¡½ºÅ×¶óÁ¦> ¾ïÁ¦Á¦.
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
  • angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • beta (¥â)-lactamase inhibitor
    º£Å¸¶ôŸ¸¶Á¦¾ïÁ¦Á¦
  • c inhibitor deficiency
    º¸Ã¼ ÀúÁöÀÎÀÚ °áÇÌÁõ(ÜÍô÷îÁò­ì×í­ÌÀù¹ñø)
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à(¡­ðæúªå·), ź»êÅ»¼öÈ¿¼ÒÀú ÇØ¹°Áú, ź»êÅ»¼ö¾ïÁ¦¾à.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹)
  • active iodine
    Ȱ¼º(üÀàõ)¿äµå
  • active mediated transport
    ´Éµ¿¸Å°³¼ö¼Û (ÒöÔÑØÚË¿âÃáê)
  • active methionine
    Ȱ¼º(üÀàõ)¸ÞŸÀÌ¿À´Ñ
  • active methyl
    Ȱ¼º(üÀàõ)¸ÞÆ¿
  • active patch
    Ȱ¼º(üÀàõ)ÆÖÄ¡
  • active phosphate
    Ȱ¼ºÀλ꿰 (üÀàõ ×òß«ç¤)
  • active phospholipid
    Ȱ¼ºÀÎÁöÁú (üÀàõ×òò·òõ)
  • active pyrophosphate
    Ȱ¼º(üÀàõ)ÇÇ·ÎÀλ꿰 (×òß«ç¤)
  • active pyruvate
    Ȱ¼º(üÀàõ)ÆÄÀÌ·çºê»ê¿° (ß«ç¤)
  • active site
    Ȱ¼º(üÀàõ)ÀÚ¸®
  • active sulfate
    Ȱ¼ºÈ²»ê¿° (üÀàõüÜß«ç¤)
  • active translocation
    Ȱ¼ºÀüÀ§ (üÀàõï®êÈ)
  • active transport
    ´Éµ¿¼ö¼Û (ÒöÔÑâÃáê)
  • flexible active site
    °¡º¯(ʦܨ) Ȱ¼º(üÀàõ)ÀÚ¸®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AA ex active assistive exercise
AAR active avoidance reaction; acute articular rheumatism; antigen-antiglobulin reaction
AB abdominal; abnormal; abortion; Ace bandage; active bilaterally; aid to the blind; alcian blue; alert...
A-CAH autoimmune chronic active hepatitis
ACD absolute cardiac dullness; absolute claudication distance; acid-citrate-dextrose [solution]; actinom...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
EACs Endocrine active compounds
HAART Highly Active Anti-Retroviral Therapy
HAART Highly Active Antiretroviral Therapies
HAART Highly active antiretroviral treatment
PAR Photosynthetically Active Radiation
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
tissue inhibitor of-metalloproteinase-3 <chemical> A member of the family of tissue inhibitor of metalloproteinases. It is a 21 kD, nonglycosylated protein. Timp-3 does not show a high degree of structural similarity unlike timp-1 and timp-2 which are structurally similar. However, it does possess a high degree of structural similarity with that of chicken timp-3 (chimp-3). Human timp-3 is of particular concern because of its potential role in cancer, arthritis, and eye diseases.
Pharmacological action: antineoplastic agent, protease inhibitors.
(12 Dec 1998)
tissue inhibitor of metalloproteinases <chemical> A family of secreted proteins (timp-1, timp-2, and timp-3) that play a crucial role in regulating the activity of the secreted metalloproteinases (collagenases, stromelysins, gelatinases). Of the three characterised, only timp-1 and timp-2 appear to have related primary structures and inhibitory properties. They influence the activation of the prometalloproteinase and act to modulate proteolysis of extracellular matrix, notably during tissue remodeling and inflammatory processes. On certain cell types, they can exhibit growth factor-like activity, and they can inhibit the tumourigenic and metastatic phenotype in cancer cells. (pharmacol ther 1993;59:329-41)
Pharmacological action: antineoplastic agent, protease inhibitors.
(12 Dec 1998)
trypsin inhibitor A peptide hydrolyzed off trypsinogen under the catalytic influence of enteropeptidase, with trypsin produced as a result; so called because the peptide masks or inhibits the active site of the trypsin molecule, one of the polypeptides, from various sources (e.g., human and bovine colostrum, soybeans, egg white), that inhibit the action of trypsin.
Compare: Bowman-Birk inhibitor.
(05 Mar 2000)
trypsin inhibitor, bowman-birk soybean <chemical> A low-molecular-weight protein (minimum molecular weight 8000) which has the ability to inhibit trypsin as well as chymotrypsin at independent binding sites. It is characterised by a high cystine content and the absence of glycine.
Pharmacological action: trypsin inhibitors.
(12 Dec 1998)
trypsin inhibitor, kazal pancreatic <chemical> A pancreatic trypsin inhibitor common to all mammals. It is secreted with the zymogens into the pancreatic juice. It is a protein composed of 56 amino acid residues and is different in amino acid composition and physiological activity from the kunitz bovine pancreatic trypsin inhibitor (aprotinin).
Chemical name: Trypsin inhibitor, pancreatic secretory
(12 Dec 1998)
trypsin inhibitor, kunitz soybean <chemical> A high-molecular-weight protein (approximately 22,500) containing 198 amino acid residues. It is a strong inhibitor of trypsin and human plasmin.
Pharmacological action: trypsin inhibitors.
Chemical name: Trypsin inhibitor, Kunitz soybean
(12 Dec 1998)
familial lipoprotein lipase inhibitor An inhibitor found in certain individuals that inhibits lipoprotein lipase resulting in accumulation of chylomicrons, VLDL, and triacylglycerols; similar in symptoms to familial lipoprotein lipase deficiency.
(05 Mar 2000)
lipoprotein-associated coagulation inhibitor Formerly known as anticonvertin; a protein that inhibits the extrinsic pathway of coagulation by binding to the tissue factor III-factor VII-Calcium-factor Xa complex.
(05 Mar 2000)
lupus coagulation inhibitor An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications.
(12 Dec 1998)
active Characterised by action, not passive, not expectant.
(18 Nov 1997)
active acetate <enzyme> Condensation product of coenzyme A and acetic acid, symbolised as CoAS~COCH3; intermediate in transfer of two-carbon fragment, notably in its entrance into the tricarboxylic acid cycle and in fatty acid synthesis.
This coenzyme plays a huge role in intermediary metabolism, in which cells synthesise, break down or use nutrient molecules for energy production, growth, etc.
Acetyl-coenzyme A synthase is found in bacteria and plants and catalyses the reaction in which acetate enters metabolic pathways and forms acetyl-coenzyme A.
Synonym: acetyl-coenzyme A, active acetate.
(05 Mar 2000)
active aldehyde Any aldehyde derivative of thiamin pyrophosphate.
(05 Mar 2000)
active anaphylaxis Reaction following inoculation of antigen in a subject previously sensitised to the specific antigen, in contrast to passive anaphylaxis.
(05 Mar 2000)
active biomass <cell biology> The amount of a given culture that is actively growing.
(06 May 1997)
active carbon dioxide Activated carbon dioxide, a complex of N-carboxybiotin (biotin + CO2) and an enzyme; the form in which carbon dioxide is added to other molecules in carboxylations; e.g., to methylcrotonyl-CoA to form beta-methylglutaconyl in the catabolism of leucine, and to acetyl-CoA to form malonyl-CoA.
See: acetyl-CoA carboxylase.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á